TruSight Oncology 500 High-ThroughputアッセイはTruSight Oncology 500アッセイをベースに、サンプルスループットとバッチオプションを向上させる柔軟性を備えています。
複数のバイオマーカーを一つのアッセイに統合
合理化されたサンプルから結果を得るまでのワークフロー
高いサンプルスループット
高い信頼性の結果を達成
施設内での包括的ゲノムプロファイリングの実現
*自動化はBeckman Coulterのi-SeriesまたはHamilton MicrolabのSTARで利用可能です。詳細は担当営業までお問い合わせください。
TruSight Oncology 500製品ポートフォリオに含まれる3つのアッセイはすべて、ガイドラインや臨床試験に含まれる重要なバイオマーカーを同定するように設計されています。
TruSight Oncology 500アッセイを用いて、FFPE腫瘍組織から重要ながんバイオマーカーを評価します。
TruSight Oncology 500アッセイ同様、同じバイオマーカーと同じ種類の組織を用いて、一回192検体まで解析できます。
TruSight Oncology 500 ctDNAアッセイを用いて血漿から血中循環腫瘍DNAを解析します。
TruSight Oncology 500 High-Throughput | TruSight Oncology 500 | TruSight Oncology 500 ctDNA | |
---|---|---|---|
Cancer Type | Pan-Cancer | Pan-Cancer | Pan-Cancer |
Content Specifications | Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size. • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Clinical Trials Coverage: Over 1,000 clinical trials • Immuno-oncology Biomarker Coverage: Biomarkers TMB and MSI included; also inclusive of HLA regions, POLE1 and POLD1* |
Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size. • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Clinical Trials Coverage: Over 1,000 clinical trials • Immuno-oncology Biomarker Coverage: Biomarkers TMB and MSI included; also inclusive of HLA regions, POLE1 and POLD1* |
|
Hands-On Time | Manual: ~10.5 hrs Automated: ~2.5 hrs |
~10.5 hours | |
Input Quantity | 40 ng DNA, 40-80 ng RNA (need at least 2 mm3 FFPE tissue) | 40 ng DNA, 40 ng RNA | |
Method | Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing | Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing | Target Enrichment, Target Enrichment, Targeted DNA Sequencing |
Nucleic Acid Type | RNA, DNA | RNA, DNA | DNA |
Sample Throughput | 16–192 samples per flow cell | ||
Specialized Sample Types | FFPE Tissue | FFPE Tissue | Blood, Circulating Tumor DNA |
Species Category | Human | Human | Human |
System Compatibility | NovaSeq 6000 | NextSeq 500, NextSeq 550, NextSeq 550Dx in Research Mode | NovaSeq 6000 |
Technology | Sequencing | Sequencing | Sequencing |
Variant Class | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Transcript Variants | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Transcript Variants | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Somatic Variants |
* 2020年3月現在、Pierian Clinical Knowledgebaseに基づく。
Simplifying the process to identify applicable variants in oncology samples
Brochure | PDF 2 MB
Optimizing RNA input to detect gene fusions with TruSight Oncology 500 High-Throughput
Technical Note | PDF < 1 MB
Data analysis and reporting for the TruSight Oncology 500 portfolio
Product Information Sheet | PDF 1 MB
Data Sheet | PDF | 7 versions
TruSight Oncology 500 High Throughput Checklist Documentation
DRAGEN TruSight Oncology 500 Analysis Software v2.1 Documentation
DRAGEN TruSight Oncology 500 Analysis Software v1.1 Documentation
DRAGEN TruSight Oncology 500 Analysis Software v1.1 on ICA Documentation
TruSight Oncology 500 v1.0 Local App Documentation
TruSight Oncology 500 Analysis Software Documentation
TruSight Oncology 500 v2.0 Local App Documentation
TruSight Oncology 500 High Throughput Consumables & Equipment Documentation
TruSight Oncology 500 v2.1 Local App Documentation
TruSight Oncology 500 v2.2 Local App Documentation
TruSight Oncology 500 High Throughput Reference Guide Documentation
カスタムプロトコルセレクタ
Generates customized, end-to-end instructions